Coronary artery disease other than atherosclerosis Arteritis Luetic Granulomatous (Takayasu disease) Polyarteritis nodosa Mucocutaneous lymph node (Kawasaki) syndrome Disseminated lupus erythematosus Rheumatoid spondylitis Ankylosing spondylitis Trauma to coronary arteries Laceration…
1 Secondary prevention Clinical history of ASCVD 2 Primary prevention LDL-C ≥190 mg/dL, age ≥21 years 3 Primary prevention Diabetes: age 40–75 years, LDL-C 70–189 mg/dL 4 Primary prevention No…
Fig. 18.1 Calcineurin/NFAT signaling plays a central role in the development of pathological cardiac hypertrophy. This pathway is an excellent example to illustrate how numerous molecules can act as modifiers…
Fig. 10.1 The schematic illustrates the main structural components of a striated muscle cell sarcomere. Thin filaments (I bands) are composed of actin monomers and tropomyosin. The thick filaments (A…
Fig. 7.1 Sudden death rates in the general population, post-myocardial infarction (MI) and in patients with reduced ejection fraction [6] 7.3 Mechanisms of Sudden Death in Heart Failure Ventricular arrhythmias…
Reference # trained Change in peak VO2 Change in QOL Morbidity and mortality Belardinelli [8] 36 15 % No difference Belardinelli [15] 50 2.9 ml/kg/min Improved Improved McKelvie [17] 90…
Fig. 1.1 ACCF/AHA stages of HF according to risk and symptoms (Reproduced with permission from JACC [5]) NYHA classes focus on exercise capacity and symptoms of HF (see Chap. 9):…
Fig. 3.1 Schematic depiction of the interrelated and (usually) opposing neurohormonal mechanisms/systems activated in acute and in chronic HF and their (patho)physiological actions for the circulation. LV left ventricular, CO…
© Springer International Publishing Switzerland 2015Gowraganahalli Jagadeesh, Pitchai Balakumar and Khin Maung-U (eds.)Pathophysiology and Pharmacotherapy of Cardiovascular Disease10.1007/978-3-319-15961-4_14 14. MicroRNA Therapeutics in Cardiovascular Disease Antoine Bril1 (1) Research and Partnerships, Institut de Recherches Internationales Servier, 50 rue…
Fig. 13.1 MicroRNAs involved in the pathogenesis of cardiovascular disease. The figure illustrates the contribution of selected miRNAs to remodeling of the heart. Manipulation of these miRNAs may hinder the…
